On 1 July 2025, Sandoz announced that it has commenced construction of a new biosimilar production centre in Brnik, Slovenia, due to open in 2028. Sandoz is investing USD 440 million in the project, which is intended to expand Sandoz’s European biosimilar hub and increase its global market reach.
The new facility will focus on the production of injectable products for Sandoz’s existing and upcoming portfolio of biosimilars and will include preparation, filling, assembly and packaging of sterile injectable products, together with laboratories for quality control.
The project will bring Sandoz’s total planned investment in Slovenia to more than USD 1.1 billion by 2029, with the company previously investing in a biosimilar drug substance centre in Lendava and a biosimilar development centre in Ljubljana.
Sandoz recently launched the first denosumab biosimilars on the US market (Jubbonti® and Wyost®, 2 June 2025) and launched biosimilar ustekinumab in the US in February 2025 (Pyzchiva®, developed by Samsung Bioepis, EU launch in July 2024). Sandoz currently has a number of biosimilars under development, including nivolumab, ipilimumab, pembrolizumab and ocrelizumab.